DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/ee380f/hospital_acquired) has announced the addition of the "Hospital Acquired Bacterial Infections Market to 2016 - Increasing Antibiotic Resistance and Increasing Population of Critically Ill Patients To Drive Growth" report to their offering.
It provides in-depth analysis of the drivers and barriers that affect the global hospital acquired bacterial infections (HABI) market. The report analyzes the markets for HABI in the US, the top five countries in Europe (the UK, Germany, France, Italy and Spain) and Japan. Treatment usage patterns, sales and price are forecast until 2016 for the key geographies as well as the leading therapeutic segments. Further, the report provides competitive benchmarking for the leading companies and analyzes the mergers, acquisitions and licensing agreements that shape the global markets.
It is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by a team of industry experts.
The Global Hospital Acquired Bacterial Infections Market is Forecast to Show Moderate Decline
In 2009, the global hospital acquired bacterial infections market was estimated to be worth $1.8 billion, representing a Compound Annual Growth Rate (CAGR) of 1.6% between 2001 and 2009. The market is forecast to reach $1.4 billion by 2016, indicating a negative CAGR of 2.9% between 2009 and 2016. The primary reason for the reduced growth rate is the patent expiries of major blockbusters, which are expected to decrease the annual cost of therapy after 2009.
The global hospital acquired bacterial infections market is expected to witness a series of patent expiries between 2009 and 2016, which includes most of the top selling blockbuster drugs in the Urinary Tract Infections (UTI), Pneumonia, Surgical Site Infections (SSI) and Blood Stream Infections (BSI) markets. The major drugs that are set to lose patent protection include Zyvox (linezolid, 2013), Levaquin (levofloxacin, 2010), Invanz (ertapenem, 2013), Tobi (tobramycin, 2014).
Acquisitions Are the Major Deal Type in the Hospital Acquired Bacterial Infections (HABI) Market Because Major Pharmaceutical Companies Are Reluctant To Invest In Anti-Bacterial R&D
The M&A deals landscape from 20042010 suggests that acquisitions are the major deal type accounting for 74% of total deals, followed by asset-transactions and mergers accounting for 13% each. This signifies that companies are reluctant to invest in anti-bacterial R&D and they prefer acquisition of companies which have developed a new molecule. There is low or zero investment in R&D for anti-bacterials by large pharmaceutical companies because of the small life-cycle of anti-bacterials as resistance is developed against them. So the investment done in R&D for anti-bacterials does not give a good return on investment
Hospital Acquired Bacterial Infections, Global, Pipeline by Phase (%), 2010
The percentage of molecules in the Phase II of development accounts for 66% to the total molecules in the pipeline. This is followed by Phase I and filed molecules which accounts for 17% each to the total pipeline molecules in the pipeline for HABI.
Scope
- Annualized market data for the HABI market from 2001 to 2009, forecast forward to 2016.
- Analysis of the leading therapeutic segments, including UTI, Pneumonia, SSI and BSI.
- Analysis of the HABI market in the leading geographies of the world, which include the US, the UK, Germany, France, Italy, Spain and Japan.
- Market characterization of the HABI market, including market size, annual cost of therapy and treatment usage patterns.
- Key drivers and barriers that have a significant impact on the market.
- Competitive benchmarking of leading companies. The key companies studied in this report are Pfizer, Eli Lily, Astrazeneca, Hoffman-La-Roche, Abbott, Novo Nordisk and Warner and Chilcott.
- Key M&A activities, licensing agreements, that have taken place since 2004 in HABI market.
Reasons to buy
- Align your product portfolio to the markets with high growth potential.
- Develop market-entry and market expansion strategies by identifying the leading therapeutic segments and geographic markets poised for strong growth.
- Develop key strategic initiatives by understanding the key focus areas of leading companies.
- Exploit in-licensing and out-licensing opportunities by identifying products that could fill portfolio gaps.
Key Topics Covered:
1 Table of Contents
2 Global Hospital Acquired Bacterial Infections Market: Introduction
3 Global Hospital Acquired Bacterial Infections Market: Market Overview
4 Global Hospital Acquired Bacterial Infections Market: Therapeutic Landscape
5 Global Hospital Acquired Bacterial Infections Market: Geographical Landscape
6 Global Hospital Acquired Bacterial Infections: Pipeline Analysis
7 Global Hospital Acquired Bacterial Infections Market: Competitive Landscape
8 Global Hospital Acquired Bacterial Infections Market: Strategic Consolidations
9 Global Hospital Acquired Bacterial Infections Market: Appendix
Companies Mentioned:
- Johnson & Johnson (J&J)
- Pfizer
- Cubist Pharmaceuticals
- Bayer
For more information visit http://www.researchandmarkets.com/research/ee380f/hospital_acquired